Redeye: Nanexa - Moments of truth closing in
Redeye reviews the Nanexa case in light of the recent development of NEX-20, its latest project NEX-22, and its collaboration with Novo Nordisk. We believe upcoming events regarding the clinical development of NEX-20 and NEX-22 bode well for the share price development, and that Nanexa’s investment agreement with Novo Nordisk could also generate shareholder value.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/